ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacoepidemiology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1494467
This article is part of the Research TopicPharmacoepidemiology in Chronic DiseasesView all 15 articles
Colopathy Associated with Pentosan Polysulfate Use
Provisionally accepted- 1School of Medicine, Duke University, Durham, North Carolina, United States
- 2School of Medicine, Emory University, Atlanta, Georgia, United States
- 3University of Georgia, Athens, Georgia, United States
- 4Bascom Palmer Eye Institute, University of Miami Health System, Miami, Florida, United States
- 5Department of Biomedical Informatics, School of Medicine, Emory University, Atlanta, Georgia, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
We describe a novel colopathy associated with pentosan polysulfate (PPS) use and assess the strength of the drug-disease association in a two-part investigation.We studied individuals with a history of long-term PPS use. Case histories concerning gastrointestinal disease were obtained through review of endoscopy records and histopathology specimens. Findings were summarized with descriptive statistics.2. Cross-Sectional Study: We evaluated patients with interstitial cystitis at a single clinical center. We obtained data on drug exposure and medical histories and measured the strength of association between PPS use and diagnoses of inflammatory bowel disease (IBD) using multivariate logistic regression.1. Cohort Study: Among 13 participants, the median PPS exposure was 2.04 kg (range 0.99-2.54 kg).Eleven participants (84.6%) developed IBD symptomatology after initiating PPS therapy, and 9 (69.2%) were diagnosed with IBD. Two others (18%) were diagnosed with irritable bowel syndrome.Of the 10 participants with endoscopic and histopathologic data, six had abnormal colonic mucosa on endoscopy, and all 10 had histologic abnormalities. Clinical and histologic improvement was noted after PPS cessation, though two (18%) required colectomy for colitis-associated dysplasia.2. Cross-Sectional Study: Among 219 subjects with interstitial cystitis, PPS use was a statistically significant predictor of an IBD diagnosis, with an adjusted odds ratio of 3.3 (95% confidence interval, 1.2-8.8, p=0.02).Our study identifies a strong association between PPS use and clinical diagnosis of IBD. Histopathologic findings suggest a novel drug-associated colopathy, with some subjects necessitating colectomy for dysplasia.Further investigation into the causality of this association is warranted.
Keywords: Pentosan polysulfate, Elmiron, interstitial cystitis, inflammatory bowel disease, Irritable Bowel Syndrome, Toxicity, Dextran Sodium Sulfate, apoptotic colopathy
Received: 10 Sep 2024; Accepted: 17 Jul 2025.
Copyright: © 2025 Jung, Zheng, Weiss, Mathew, Meyer, Nizam, Iskandar and Jain. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Nieraj Jain, School of Medicine, Emory University, Atlanta, 30322, Georgia, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.